1

SPL An Introduction
SPL ranks 398 in the prestigious FORTUNE India 500 list & Ranked no: 20 in Indian Pharmaceutical Sector

The Company is one of the largest exporters of Mint/Menthol derivatives

Revenue of over USD 250 mm

SPL has been awarded EXCELLENT SUPPLIER (Best Competitiveness) AWARD OFTHE one of the biggest Pharmaceutical manufacturers in Hong KongYEAR by Bright Future Pharmaceutical laboratories Ltd,!!

Professionally Manage

A Trusted Indian Brand

Strong Internal Competencies

World class Manufacturing & R&D Strong Supply Chain & fastest growing company

Surya Corp
Established in the year 1992, Surya Pharmaceutical Ltd today is one of the leading integrated and multidimensional pharmaceutical group of India which is growing and expanding very fast A stronghold in API- especially B-LACTUMS and CEPHALOSPORINES with 8 state of the art manufacturing units Largest producer & exporter of Menthol & menthol based products to more than 90 countries Branded formulations with 6 SBUS Covering various Therapeutic segments including nutritional products

is operational at PAN India level.

Surya Corp. is having its own chain of retail pharmacy stores with the Brand name of VIVA spreaded over North India. At present We have 100 Pharmacy Stores which are likely to increase upto 250 by the end of 2011. OTC / FMCG business venture is also launched.

A Group worth INR 1200 crores ( USD 250 millions)

SPL ranks 398 in the prestigious FORTUNE India 500 list & Ranked no: 20 in Indian Pharmaceutical Sector

SPL has ranked 398 in the prestigious FORTUNE India 500 list! The Fortune India 500 list features India`s LARGEST CORPORATIONS!
Not only that, it outranked Pharmaceutical giants like Aventis Pharma, Alembic, Arch Pharmalabs and Ankur Drugs to climb to number 20 in the top Drugs & Pharmaceuticals companies of India!

Companies in the Fortune 500 list are ranked on the parameters of both Revenue & Income, they are ranked by their latest annual audited total income for the financial year ending on or before June 30, 2010. The Total Income includes Core Operating Income ( Net sales) plus other Extraordinary Income. Audited results declared before October 31st, 2010 have been used for the calculations. The numbers have been sourced from two corporate databases- the Centre for Monitoring of Indian Economies Prowess and Capitaline Plus by Capital Market Publishers India.

Surya Group

Brand The Power Brand Strategy

Diabetic Footwear

Diagnostic and Medical Devices

Personal care

Baby care

Sports Nutrition Supplement

Foot Care Medical shoes for diabetic patients

OTC Health Care BP Monitors

Skin Care Baby Care Lip Care

Skin Care Feeding Bottles

Bodybuildin g Nutrition Weight Managemen t Nutrition

Classical Diabetic Neuropat hy

Glucose Monitor

A Three Pronged Strategy for Sustaining Growth

EXPAND

ACQUIRE

INNOVATE

Strategic Intent To double revenues and profits in the next coming years.

SPL On The Growth Path Sales in crores 2004 to 2010

1400 1200 1000 800 600 400 200 0 Sales Growth 2004

2005
2006 2007 2008 2009 2010

Surya Pharmaceutical Ltd Growth Trends

Net Profit 2004 to 2010

Surya Pharmaceutical Ltd Annual Report 2009-2010 Cash & Net Profit